Clinical Study
Safety and Feasibility of Repeated Intrathecal Allogeneic Bone Marrow-Derived Mesenchymal Stromal Cells in Patients with Neurological Diseases
Table 10
Comparison of adverse events among clinical studies of intrathecal autologous MSCs, allogeneic MSCs, and non-MSCs stem cells.
| ||||||||||||||||||||||||||||||||||||||||
a compared with autologous MSCs. b compared with allogeneic MSCs. |